Invikafusp Alfa

N/A

Report date: 2025/09/25 13:53:39
First In Class

Base Information

Drug NameInvikafusp Alfa
Drug Alias NameSelective T Cell Activation Repertoire-0602STAR0602STAR-0602
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-TRBC1Antibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsTRBC1
Therapy Area/IndicationsSolid tumoursVulvar DiseasesVulvar Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMarengo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAdvanced Technology Products CorpMarengo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursVulvar DiseasesVulvar Neoplasms +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A